Dernières nouvelles pour Otis Worldwide (NYSE:OTIS) Stock

Otis Worldwide

Otis Worldwide Corp is the largest global elevator and escalator supplier by revenue with around 18% global market share. In 1854 Otis' founder and namesake Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed. The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15- to 20-year useful life of an elevator. As the largest global OEM, Otis has amassed an installed base under service that exceeds 2 million elevators. Its business model is similar to that of its closest competitors Kone, Schindler, and TK Elevator.

Otis Worldwide Corp

B of A Securities analyst John Babcock maintains Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) with a Underperform and lowers the price target from $3.3 to $2.7.

News

Price Target

Analyst Ratings

B of A Securities Maintains Underperform on Hertz Global Holdings, Lowers Price Target to $2.7

Telsey Advisory Group analyst Dana Telsey maintains Capri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) with a Market Perform and lowers the price target from $23 to $17.

CPRI

Telsey Advisory Group Maintains Market Perform on Capri Holdings, Lowers Price Target to $17

Earnings

Morgan Stanley Q1 Investment Banking Revenues Up 8%, Equity Net Revenues Up 45%, Fixed Income Net Revenues Up 5%

Telsey Advisory Group analyst Joe Feldman maintains Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with a Outperform and maintains $26 price target.

Telsey Advisory Group Maintains Outperform on Albertsons Companies, Maintains $26 Price Target

B of A Securities analyst Muneeba Kayani maintains ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) with a Underperform and lowers the price target from $16 to $12.8.

B of A Securities Maintains Underperform on ZIM Integrated Shipping, Lowers Price Target to $12.8

B of A Securities analyst Allen Lutz maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral and lowers the price target from $9.5 to $8.

TDOC

B of A Securities Maintains Neutral on Teladoc Health, Lowers Price Target to $8

Rosenblatt analyst Kevin Cassidy maintains Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy and maintains $8 price target.

Rosenblatt Maintains Buy on Canaan, Maintains $8 Price Target

Iran on Friday expressed its willingness to engage in high-level nuclear discussions with the United States. 
What Happened: President Donald Trump on Monday unexpectedly announced the upcoming talks, scheduled to take place in Oman. 
This development comes in the wake of President Trump&#8217;s <a href="https://www.benzinga.com/government/regulations/25/04/44674785/trump-vows-to-reset-global-trade-warns-iran-faces-great-danger-if-talks-fail">recent threat of military action</a> should the talks fail. Oman has a history of serving as a mediator between the West and Iran.
Iran's foreign ministry urged the U.S. to appreciate Tehran's willingness to pursue dialogue, despite what it described as Washington's ongoing "aggressive theatrics."
Iranian spokesperson Esmaeil Baghaei posted on X, &#8220;We intend to assess the other side's intent and resolve this Saturday.&#8221; 
&#8220;In earnest and with candid vigilance, we are giving diplomacy a genuine chance.&#8221;
See Also:&nbsp;<a href="https://benzinga.com/markets/25/04/44728777/pence-calls-trumps-tariff-moves-misstep-cites-potential-economic-harm-to-working-families" target="_blank" rel="noreferrer noopener">Former Vice President Mike Pence Calls Trump&#8217;s Tariff Moves &#8216;Misstep,&#8217; Cites Potential Economic Harm To Working Families</a>
Why It Matters: Since retaking office in January, Trump has intensified his approach toward Iran, which Israel — a close U.S. ally — views as a major threat due to its advancing nuclear program.
Israel&#8217;s military operations, including airstrikes within Iranian territory, have further strained the region. These actions followed a wave of violence in October 2023, when Hamas launched attacks against Israel, prompting a broader response that also impacted Iran and its regional allies.
The decision to engage in talks comes after Iran&#8217;s Supreme Leader, Ayatollah Ali Khamenei, <a href="https://www.benzinga.com/news/global/25/03/44211072/iran-dismisses-trumps-nuclear-negotiation-proposal-accuses-us-of-coercion">dismissed</a> Trump&#8217;s peace negotiation proposal in early March, accusing the U.S. of trying to &#8220;bully&#8221; Iran into compliance. This shift in stance could be a result of the mounting pressure from Israel&#8217;s military offensives and U.S. air strikes on Iran-aligned groups. Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:&nbsp;<a href="https://benzinga.com/markets/25/04/44755977/xi-jinping-steering-clear-of-trump-negotiations-to-avoid-political-backlash-at-home-says-expert-china-doe" target="_blank" rel="noreferrer noopener">Xi Jinping Steering Clear Of Trump Negotiations To Avoid Political Backlash At Home, Says Expert: China &#8216;Doesn&#8217;t Have Any Cards In This&#8217; Game</a>

Politics

General

Iran Signals Openness To Nuclear Talks With US, Warns Against Trump's 'Aggressive Theatrics'

Piper Sandler analyst Peter Keith maintains Sleep Number (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNBR#NASDAQ">SNBR</a>) with a Neutral and lowers the price target from $11 to $6.

SNBR

Piper Sandler Maintains Neutral on Sleep Number, Lowers Price Target to $6

Ripple Labs and the U.S. Securities and Exchange Commission are moving toward a final resolution of <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44398151/ripple-ceo-announces-victory-as-sec-drops-appeal-in-xrp-lawsuit">their lengthy legal battle</a>, as both parties formally requested a pause on their respective appeals in court.
What Happened: The joint <a href="https://www.courtlistener.com/docket/69230851/60/securities-and-exchange-commission-v-ripple-labs-inc/">filing</a>, submitted to the U.S. Court of Appeals for the Second Circuit, confirms that an agreement-in-principle has been reached and the parties are now working toward finalizing it.
The filing states that additional time is needed for the SEC to secure formal approval of the settlement and to obtain a ruling from the district court. 
Legal representatives from both Ripple and the SEC signed the document, marking the first formal indication that the appeals process may be concluding.
The SEC's appeal, originally filed in October 2023, challenged prior rulings related to Ripple's sale of XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>).
Ripple had also filed a cross-appeal. 
Both actions are now being dropped, pending final approval by the Commission.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44747802/block-fined-40-million-by-new-york-regulator-over-cash-app-compliance-failures">Block Fined $40 Million By New York Regulator Over Cash App Compliance Failures</a>
Why It Matters: This development follows Ripple CEO Brad Garlinghouse's statement last month suggesting that the SEC intended to withdraw its challenge.
While the resolution is still contingent on formal SEC approval, it is expected to proceed following the recent Senate confirmation of incoming SEC Chair Paul Atkins.
The case, initiated in December 2020, alleged that Ripple conducted a $1.3 billion unregistered securities offering through XRP sales. 
However, in July 2023, Judge Analisa Torres ruled that secondary market sales of XRP did not qualify as securities offerings—a partial win for Ripple.
Since Donald Trump's election victory, XRP has surged nearly 300%, fueled by optimism over a friendlier regulatory environment.
Despite today's confirmation of appeal withdrawals, the token rose only 0.2% in the last 24 hours, indicating that the news may already be priced in by investors.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44739006/crypto-leverage-trading-in-the-us-may-become-more-accessible-heres-why">Crypto Leverage Trading In The US May Become More Accessible: Here&#8217;s Why</a></li>
</ul>
Image: Shutterstock

$XRP

Ripple, SEC Move To End Legal Dispute As Both Sides Withdraw Appeals

D. Boral Capital analyst Jason Kolbert maintains Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy and maintains $36 price target.

OMER

D. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target

Piper Sandler analyst Anna Andreeva maintains Warby Parker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) with a Overweight and lowers the price target from $30 to $20.

WRBY

Piper Sandler Maintains Overweight on Warby Parker, Lowers Price Target to $20

Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and maintains $111 price target.

MMSI

Barrington Research Maintains Outperform on Merit Medical Systems, Maintains $111 Price Target

Seaport Global analyst Angie Storozynski maintains SJW Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SJW#NASDAQ">SJW</a>) with a Buy and lowers the price target from $61 to $59.

Seaport Global Maintains Buy on SJW Gr, Lowers Price Target to $59

Piper Sandler analyst Anna Andreeva maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Neutral and lowers the price target from $18 to $12.

Piper Sandler Maintains Neutral on VF, Lowers Price Target to $12

WIIM

Morgan Stanley shares are trading higher after the company reported better-than-expected Q1 financial results.

Piper Sandler analyst Anna Andreeva maintains Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Neutral and lowers the price target from $35 to $25.

SHOO

Piper Sandler Maintains Neutral on Steven Madden, Lowers Price Target to $25

Barrington Research analyst Gary Prestopino maintains Snap-on (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>) with a Outperform and maintains $350 price target.

Barrington Research Maintains Outperform on Snap-on, Maintains $350 Price Target

Presentation highlighted the recent expansion of the Phase 3 SELVA trial to include children 3 to 5 years old
Presentation reviewed clinically and statistically significant Phase 2 results and the design of the ongoing Phase 3 SELVA trial
Top-line results from SELVA remain on track for the first quarter of 2026
QTORIN&#x2122; 3.9% rapamycin anhydrous gel has the potential to be the first approved therapy and standard of care for microcystic lymphatic malformations in the U.S.
WAYNE, Pa., April 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVLA#NASDAQ">PVLA</a>) <a href="https://www.globenewswire.com/Tracker?data=lzncM9foe2Qc92V3o07-pkBSFRH1fPIBCLlZaC0z-zJ2jurIMhv9hDRX39DI_WtQpEu9SRWU0qcJcNyY3lBN-uNcZgEh27Doi8rppmzyTVE=">Palvella Therapeutics, Inc.</a> (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced QTORIN&#x2122; rapamycin 3.9% anhydrous gel (QTORIN&#x2122; rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) was featured by Dr. Amy Paller in an oral presentation at the 15th World Congress of Pediatric Dermatology in&nbsp;Buenos Aires, Argentina. Dr. Amy Paller is the Walter J. Hamlin Professor and Chair of Dermatology, Professor of Pediatrics, and Principal Investigator of the NIH-funded Skin Biology and Diseases Resource-based Center at Northwestern University's Feinberg School of Medicine and has served as President of the Society for Investigative Dermatology (SID), the Society for Pediatric Dermatology (SPD), the International Eczema Council (IEC), the Pediatric Dermatology Research Alliance (PeDRA), and the Women's Dermatological Society (WDS).
"There is an urgent need for a safe and effective targeted topical therapy for mosaic genetic skin disorders including microcystic lymphatic malformation," said Amy Paller, M.S., M.D., Chair of Dermatology, Northwestern University's Feinberg School of Medicine. "Many patients have considerable complications associated with this disease, and I am looking forward to the Phase 3 results early next year."
The oral presentation titled, "SELVA: A Phase 3 study with a fit-for-purpose primary endpoint evaluating QTORIN&#x2122; 3.9% rapamycin anhydrous gel in the treatment of microcystic lymphatic malformations in patients 3 years of age and older," highlighted:
<ul>
<li>Microcystic LMs are congenital mosaic lesions that gradually increase in size with risk of complications and are best managed aggressively during childhood</li>
<li>Microcystic LMs are proliferative with no spontaneous regression</li>
<li>QTORIN&#x2122; rapamycin, an investigational therapy designed to selectively inhibit the mammalian target of rapamycin (mTOR) in the skin, potentially reduces endothelial cell hyper-proliferation and vascular endothelial growth factor signaling, both of which are the result of overactive mTOR signaling in microcystic LMs</li>
<li>A multicenter, open-label, 12-week, Phase 2 study evaluating the safety and efficacy of QTORIN&#x2122; rapamycin for microcystic LMs demonstrated:
<ul>
<li>100% of participants were either "Very Much Improved" (41.7%) or "Much Improved" (58.3%) as rated by the Clinician Global Impression of Change (CGI-C), a 7-point change scale conducted by live clinician assessment</li>
<li>83% of participants were either "Very Much Improved" (25%) or "Much Improved" (58.3%) as rated by the Patient Global Impression of Change, a 7-point change scale reported by patients</li>
<li>QTORIN&#x2122; rapamycin was generally well-tolerated; all treatment related adverse events were moderate or mild and there were no discontinuations due to adverse events.</li>
</ul>
</li>
<li>SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN&#x2122; rapamycin for the treatment of microcystic LMs, mimics the Phase 2 study, with key study elements including the following:
<ul>
<li>Based on data from Phase 2 and clinician interviews, the primary endpoint is the fit-for-purpose Microcystic Lymphatic Malformations Investigator's Global Assessment (mLM-IGA), a 7-point change scale conducted by live clinician assessment with similarities to the CGI-C</li>
<li>Patient population enriched to include patients with moderate to severe disease</li>
<li>Target sample size of 40 subjects</li>
<li>Treatment duration extended to 24-weeks</li>
<li>Enrollment criteria expanded to include patients 3 years and older</li>
</ul>
</li>
</ul>
"Microcystic LMs are a serious, rare, and chronically debilitating genetic disease with a pediatric onset and lifelong course. Early intervention is essential to minimizing disease burden for this patient population who currently have no FDA-approved therapies. Palvella is pleased to include patients younger than 6 years old in the ongoing Phase 3 SELVA study," said Wes Kaupinen, Founder and Chief Executive Officer of Palvella.
SELVA is currently enrolling patients at 13 centers in the United States. Top-line data is anticipated in the first quarter of 2026. The U.S. FDA has granted Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation to QTORIN&#x2122; rapamycin for the treatment of microcystic LMs. Additionally, the SELVA study is supported by an Orphan Products Grant of up to $2.6 million from FDA's Office of Orphan Products Development.

PVLA

Palvella Therapeutics' QTORIN Rapamycin For Microcystic LMs Treatment Featured By Dr. Amy Paller In Oral Presentation At 15Th World Congress Of Pediatric Dermatology In Buenos Aires, Argentina

Barrington Research analyst Alexander Paris maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and maintains $112 price target.

Barrington Research Maintains Outperform on HealthEquity, Maintains $112 Price Target

Press Releases

Otis CEO to Speak at Morgan Stanley Conference

Students to Develop Urban Mobility Solutions Using AI

Otis Third Quarter 2024 Earnings Advisory

OTIS REPORTS THIRD QUARTER 2024 RESULTS

Dividends

Otis Declares Quarterly Dividend of $0.39 per Share

Otis Fourth Quarter 2024 Earnings Advisory

Otis Authorizes $2 Billion for Share Repurchase

OTIS REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS

Otis First Quarter 2025 Earnings Advisory

OTIS

Crane

Donaldson

Dover

ESAB

Flowserve

Fortive

Graco

Chart Industries

IDEX

Ingersoll Rand

Illinois Tool Works

JBT Marel

Lincoln Electric Holdings, Inc. - Common Shares

Lincoln Electric Holdings

Middleby

Mueller Industries

Nordson

Parker Hannifin

Pentair

RBC Bearings

Snap-on

SPX Technologies

Stanley Black & Decker, Inc. Common Stock

Stanley Black & Decker

Watts Water Technologies, Inc. Class A Common Stock

Comments

Otis Worldwide

Actualités

Dernières nouvelles pour Otis Worldwide (NYSE:OTIS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL